Related Experiment Videos
Comparison of in-hospital secondary prevention for different vascular diseases
Andreas Perren1, Bernard Cerutti, Mario Lazzaro
1Intensive Care Unit, Ospedale Regionale Bellinzona e Valli, Bellinzona, Switzerland. andreas.perren@eoc.ch
Insights
Secondary prevention drug adherence is similar across vascular diseases like coronary artery disease, peripheral artery disease, and cerebrovascular disease. However, only about one-third of patients receive a complete set of recommended prophylactic medications.
Area of Science:
- Cardiology
- Vascular Medicine
- Pharmacology
Background:
- Secondary prevention of coronary artery disease (CAD) is well-established and widely practiced.
- Adherence to secondary prevention guidelines for other vascular diseases remains understudied.
- This study investigates if disease type impacts secondary drug prophylaxis prescription at hospital discharge.
Purpose of the Study:
- To compare secondary drug prophylaxis prescription practices across different vascular diseases.
- To assess the completeness of secondary prevention medication bundles at hospital discharge.
- To identify potential disparities in care based on vascular disease type.
Main Methods:
- Prospective observational study over 3 months.
- Inclusion of patients hospitalized for coronary artery disease (acute myocardial infarction [AMI], chronic stable angina [CSA]), peripheral artery disease (PAD), and cerebrovascular disease (CVD).
- Analysis of hospital discharge information by registered internists using a structured form based on international recommendations.
Main Results:
- A total of 271 patients were analyzed: 191 with CAD, 88 with PAD, and 72 with CVD.
- Global prescription rates for indicated secondary prophylaxis drugs were comparable across conditions (72.1%–74.7%).
- Only 29.5% of patients received a complete bundle of recommended secondary prevention medications.
Conclusions:
- Prescription rates for secondary prevention drugs are similar regardless of vascular disease type.
- A significant gap exists in the completeness of prescribed secondary prevention medication regimens.
- Further interventions are needed to ensure comprehensive secondary drug prophylaxis for all vascular disease patients.
Background:
Secondary prevention of coronary artery disease is highly effective and implemented on a large scale. However, studies testing adherence to recommended secondary prevention of other vascular diseases are rare. Our goal was to evaluate whether the kind of vascular disease influences prescription practice of secondary drug prophylaxis at hospital discharge and to which extent secondary prevention is actually complete.
Methods:
A 3-month prospective observational review of the hospital discharge information of all patients hospitalized because of a vascular disease diagnosis: coronary artery disease (i.e. acute myocardial infarction [AMI] and chronic stable angina [CSA]); peripheral artery disease [PAD] and cerebrovascular disease [CVD]. The analysis was done by board registered internists with a structured form that founded on internationally accepted recommendations.
Results:
From 271 patients 191 had coronary artery disease (105 AMI and 86 CSA), 88 PAD and 72 CVD. Global prescription rate (mean; 95% CI) of indicated secondary prophylaxis drugs was 74.1% (69.9-78.2) for AMI, 72.4% (67.2-77.5) for CSA, 74.7% (68.8-80.7) for PAD and 72.1% (66.9-77.3) for CVD. The proportion of patients who were prescribed a complete bundle of recommended medications was globally 29.5% (24.1-35.0).
Conclusions:
We found similar global prescription rates of secondary prevention for the different vascular diseases. However, only one third of the studied collective gets a complete set of required prophylactic drugs.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Peripheral Artery Disease III: Interprofessional Care
Coronary Artery Disease V: Interprofessional Care
Peripheral Artery Disease V: Postoperative Nursing Management
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation
Coronary Artery Disease IV: Preventive Measures